Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An efficacy study of a single dose treatment of PRO-513 [diclofenac potassium; ProEthic Pharmaceuticals] for subjects suffering a migraine attack

X
Trial Profile

An efficacy study of a single dose treatment of PRO-513 [diclofenac potassium; ProEthic Pharmaceuticals] for subjects suffering a migraine attack

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diclofenac potassium (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Kowa Pharmaceuticals America
  • Most Recent Events

    • 13 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
    • 26 Oct 2010 Results of this and another pivotal safety and efficacy study of CAMBIA will be presented at the 4th World Congress on Controversies in Neurology Conference (CONy), according to a Nautilus Neurosciences media release.
    • 08 Apr 2010 Secondary endpoint 'Sustained response' has been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top